Common Skin Side Effects of Rinvoq
Rinvoq (upadacitinib), a JAK inhibitor for conditions like rheumatoid arthritis, psoriasis, and atopic dermatitis, commonly causes skin reactions. These affect 10-20% of users in clinical trials, including acne (up to 10%), rash (5-10%), and herpes zoster-related skin eruptions (shingles rash, 3-7%).[1][2]
Serious Skin Reactions and Warnings
Black box warnings highlight risks of serious infections, including skin infections like cellulitis or herpes zoster, which can lead to painful, blistering rashes. Rare but severe effects include Stevens-Johnson syndrome (blistering, peeling skin) and drug reaction with eosinophilia and systemic symptoms (DRESS), with fever, rash, and organ involvement. Discontinue if these occur.[1][3]
How Often Do They Happen by Condition?
- Atopic dermatitis trials: Acne (6-16%), rash (5%), folliculitis (hair follicle inflammation, 2-4%).[2]
- Rheumatoid arthritis: Rash (4%), acne (3%).[1]
- Psoriasis: Less frequent new skin issues, but monitor for worsening plaques or infections (2-5%).[4]
Higher doses (30 mg) increase risks compared to 15 mg.[1]
What Triggers or Worsens Skin Side Effects?
Immunosuppression from Rinvoq raises shingles risk, especially in those over 50 or unvaccinated (recommend Shingrix vaccine before starting). Photosensitivity or injection-site reactions occur in under 2%, but UV exposure can aggravate rashes.[1][3]
How Do Patients Describe Rinvoq Skin Issues?
User reports on forums note cystic acne, dry/flaky skin, or itchy red bumps starting 1-4 weeks in, sometimes resolving after months or dose adjustment. Eczema flares paradoxically affect some atopic dermatitis patients.[5]
Management and When to Call a Doctor
Topical steroids or antibiotics treat mild cases; dose reduction or pausing helps moderate ones. Seek care for spreading rash, blisters, fever, or pain—could signal infection.[1][3] No direct link to long-term scarring, but monitor with dermatologist.
[1]: Rinvoq Prescribing Information (AbbVie, 2023)
[2]: FDA Label for Rinvoq (Atopic Dermatitis)
[3]: Rinvoq Safety Profile (FDA)
[4]: Clinical Trials Data (NEJM, 2021)
[5]: Drugs.com User Reviews